A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Trastuzumab
Sponsor: Hoffmann-La Roche